Products
Rezorstobart Biosimilar Monoclonal Antibody (CD161) for Research
Cat No.: GMP-Bios-INN-1368
Anti-KLRB1 therapeutic antibody (Pre-made Rezorstobart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Rezorstobart (development code IMT009) is a monoclonal antibody targeting KLRB1. It is developed by Immunitas Therapeutics for Lymphoma, Solid tumours, Glioma in Phase I/II development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1368-1mg | 1mg | 3090 |
| GMP-Bios-INN-1368-10mg | 10mg | |
| GMP-Bios-INN-1368-100mg | 100mg | |
| GMP-Bios-INN-1368-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Rezorstobart biosimilar, Whole mAb, Anti-KLRB1 Antibody: Anti-CD161/KLRB1/Killer cell lectin-like receptor subfamily B member 1/C-type lectin domain family 5 member B therapeutic antibody |
| INN Name | Rezorstobart |
| Target | KLRB1 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I/II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2023 |
| Year Recommended | 2024 |
| Companies | Immunitas Therapeutics |
| Conditions Approved | na |
| Conditions Active | Lymphoma;Solid tumours;Glioma |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
